Literature DB >> 10854696

Mouse receptor-activity-modifying proteins 1, -2 and -3: amino acid sequence, expression and function.

K Husmann1, P M Sexton, J A Fischer, W Born.   

Abstract

The calcitonin receptor-like receptor (CRLR) requires novel receptor-activity-modifying proteins (RAMPs) for its function as an adrenomedullin (ADM) or a calcitonin (CT) gene-related peptide (CGRP) receptor. Here, mouse cDNA clones representing expressed sequence tags (ESTs) in the GenEMBL database have been identified. They encode for proteins with 70, 68 and 84% amino acid sequence identity with respect to human RAMP1, -2 and -3. On Northern blot analysis of polyA(+) RNA mouse RAMP1 (mRAMP1) encoding mRNA with an apparent size of 0.8 kb was predominantly observed in embryonic and adult brain and lung and in adult skeletal muscle. Mouse RAMP2 encoding 0.8 and 1.2 kb mRNA were recognized in all tissues analyzed with the highest levels in embryonic brain, lung and gut and in adult heart, lung, skeletal muscle and brain. A single 1.2 kb mRAMP3 encoding transcript was mainly expressed in embryonic and adult brain. In COS-7 cells co-expressing rat CRLR (rCRLR) and mRAMP1, [125I]halphaCGRP binding was inhibited by ralphaCGRP(8-37), ralphaCGRP and rbetaCGRP with IC(50) of 1.4+/-0.5, 4.5+/-0.6 and 7+/-0.3 nM, respectively. CyclicAMP accumulation was maximally stimulated tenfold by rbetaCGRP and ralphaCGRP with EC(50) of 0. 65+/-0.67 and 0.86+/-0.6 nM. In the same cells co-expressing rCRLR and mRAMP2, binding of [125I]rADM was displaced by rADM and rADM(20-50) with IC(50) of 1.9+/-0.5 and 3.4+/-1.4 nM, respectively, and a maximal sevenfold stimulation of cAMP accumulation was observed with rADM with an EC(50) of 0.82+/-0.85 nM. In the cells co-expressing rCRLR and mRAMP3, [125I]halphaCGRP binding was inhibited by ralphaCGRP(8-37), rbetaCGRP, ralphaCGRP, rADM and rADM(20-50) with IC(50) between 4 and 22 nM. cAMP accumulation was stimulated by rADM with an EC(50) of 5.1+/-2.7 nM that was 12-fold and 11-fold lower than that of ralphaCGRP and rbetaCGRP. In conclusion, mouse RAMP1, -2 and -3 exhibit high amino acid sequence homology to the corresponding human RAMPs. Co-expression of rCRLR with mRAMP1, -2 or -3 in COS-7 cells revealed distinct CGRP-, ADM- or ADM/CGRP receptors.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10854696     DOI: 10.1016/s0303-7207(00)00212-4

Source DB:  PubMed          Journal:  Mol Cell Endocrinol        ISSN: 0303-7207            Impact factor:   4.102


  14 in total

1.  Receptor-activity-modifying protein 1 forms heterodimers with two G-protein-coupled receptors to define ligand recognition.

Authors:  K Leuthäuser; R Gujer; A Aldecoa; R A McKinney; R Muff; J A Fischer; W Born
Journal:  Biochem J       Date:  2000-10-15       Impact factor: 3.857

Review 2.  The pharmacology of adrenomedullin receptors and their relationship to CGRP receptors.

Authors:  Debbie L Hay; Alex C Conner; Stephen G Howitt; David M Smith; David R Poyner
Journal:  J Mol Neurosci       Date:  2004       Impact factor: 3.444

3.  Adrenomedullin upregulates M2-muscarinic receptors in cardiomyocytes from P19 cell line.

Authors:  Sophie Buys; Fatima Smih; Atul Pathak; Pierre Philip-Couderc; Patrick Verwaerde; Jean-Louis Montastruc; Philippe Rouet; Jean-Michel Senard
Journal:  Br J Pharmacol       Date:  2003-07       Impact factor: 8.739

4.  Loss of receptor activity-modifying protein 3 exacerbates cardiac hypertrophy and transition to heart failure in a sex-dependent manner.

Authors:  Cordelia J Barrick; Patricia M Lenhart; Ryan T Dackor; Elizabeth Nagle; Kathleen M Caron
Journal:  J Mol Cell Cardiol       Date:  2011-11-04       Impact factor: 5.000

5.  Identification of RL-TGR, a coreceptor involved in aversive chemical signaling.

Authors:  Staci P Cohen; Karla K V Haack; Gwyneth E Halstead-Nussloch; Karen F Bernard; Hanns Hatt; Julia Kubanek; Nael A McCarty
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-21       Impact factor: 11.205

Review 6.  Class II G protein-coupled receptors and their ligands in neuronal function and protection.

Authors:  Bronwen Martin; Rakel Lopez de Maturana; Randall Brenneman; Tom Walent; Mark P Mattson; Stuart Maudsley
Journal:  Neuromolecular Med       Date:  2005       Impact factor: 3.843

7.  CL/RAMP2 and CL/RAMP3 produce pharmacologically distinct adrenomedullin receptors: a comparison of effects of adrenomedullin22-52, CGRP8-37 and BIBN4096BS.

Authors:  D L Hay; S G Howitt; A C Conner; M Schindler; D M Smith; D R Poyner
Journal:  Br J Pharmacol       Date:  2003-08-26       Impact factor: 8.739

8.  Cardiovascular effects of exogenous adrenomedullin and CGRP in Ramp and Calcrl deficient mice.

Authors:  J B Pawlak; S E Wetzel-Strong; M K Dunn; K M Caron
Journal:  Peptides       Date:  2016-12-08       Impact factor: 3.750

9.  A comparison of the actions of BIBN4096BS and CGRP(8-37) on CGRP and adrenomedullin receptors expressed on SK-N-MC, L6, Col 29 and Rat 2 cells.

Authors:  Debbie L Hay; Stephen G Howitt; Alex C Conner; Henri Doods; Marcus Schindler; David R Poyner
Journal:  Br J Pharmacol       Date:  2002-09       Impact factor: 8.739

10.  Pharmacological characterisation of mouse calcitonin and calcitonin receptor-like receptors reveals differences compared with human receptors.

Authors:  Michael L Garelja; Rebekah L Bower; Margaret A Brimble; Shanan Chand; Paul W R Harris; Muhammad Aqfan Jamaluddin; Jakeb Petersen; Andrew Siow; Christopher S Walker; Debbie L Hay
Journal:  Br J Pharmacol       Date:  2021-10-15       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.